RNAi therapeutics for CNS disorders

被引:35
|
作者
Boudreau, Ryan L. [1 ]
Davidson, Beverly L. [1 ,2 ]
机构
[1] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA
关键词
RNAi; Therapy; Neurodegenerative; Huntington's; Alzheimer's; Parkinson's; Ataxias; DOUBLE-STRANDED-RNA; SMALL INTERFERING RNA; POLYGLUTAMINE-INDUCED NEURODEGENERATION; HUNTINGTONS-DISEASE; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; PROLONGS SURVIVAL; MUTANT SOD1; TRANSGENIC MICE; GENE-EXPRESSION;
D O I
10.1016/j.brainres.2010.03.038
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
RNA interference (RNAi) is a process of sequence-specific gene silencing and serves as a powerful molecular tool to manipulate gene expression in vitro and in vivo. RNAi technologies have been applied to study gene function and validate drug targets. Researchers are investigating RNAi-based compounds as novel therapeutics to treat a variety of human diseases that are currently lacking sufficient treatment. To date, numerous studies support that RNAi therapeutics can improve disease phenotypes in various rodent models of human disease. Here, we focus on the development of RNAi-based therapies aimed at treating neurological disorders for which reduction of mutant or toxic gene expression may provide clinical benefit. We review RNAi-based gene-silencing strategies, proof-of-concept studies testing therapeutic RNAi for CNS disorders, and highlight the most recent research aimed at transitioning RNAi-based therapeutics toward clinical trials. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:112 / 121
页数:10
相关论文
共 50 条
  • [31] RNAi therapeutics -: SNALPing siRNAs in vivo
    Rossi, JJ
    GENE THERAPY, 2006, 13 (07) : 583 - 584
  • [32] RNAI THERAPEUTICS SCREENING FOR GENE THERAPY
    Zhu, York
    French, Peter
    Peng, Wei
    Lu, Yi-Xiang
    Li, Tie-Jun
    Sun, Yun-Cheng
    Tang, Xiao-Jun
    Shan, Li
    Chen, Jay
    Wang, Jinkang
    JOURNAL OF GENE MEDICINE, 2011, 13 (7-8): : 417 - 418
  • [33] Are RNAi and miRNA therapeutics truly dead?
    Conde, Joao
    Artzi, Natalie
    TRENDS IN BIOTECHNOLOGY, 2015, 33 (03) : 141 - 144
  • [34] An Eye-opener for RNAi Therapeutics
    Berkhout, Ben
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2008, 107 (10) : 749 - 750
  • [35] Emerging Approaches for Enabling RNAi Therapeutics
    Mallick, Argha M.
    Tripathi, Archana
    Mishra, Sukumar
    Mukherjee, Asmita
    Dutta, Chiranjit
    Chatterjee, Ananya
    Sinha Roy, Rituparna
    CHEMISTRY-AN ASIAN JOURNAL, 2022, 17 (16)
  • [36] RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies
    Malhotra, Meenakshi
    Toulouse, Andre
    Godinho, Bruno M. D. C.
    Mc Carthy, David John
    Cryan, John F.
    O'Driscoll, Caitriona M.
    MOLECULAR BIOSYSTEMS, 2015, 11 (10) : 2635 - 2657
  • [37] Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders
    Shah, Pranav
    Lalan, Manisha
    Barve, Kalyani
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [38] MEDI 385-Toward PPAR agonists as novel therapeutics for inflammation and CNS disorders
    Mehra, Upasana
    Lin, Jack J.
    Habets, Gaston
    Ibrahim, Prabha N.
    Artis, Rick
    Zhang, Chao
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [39] Peptide therapeutics for CNS indications
    McGonigle, Paul
    BIOCHEMICAL PHARMACOLOGY, 2012, 83 (05) : 559 - 566
  • [40] The Potential RNAi-based Combination Therapeutics
    Jung, Hun Soon
    Shin, Young Kee
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (01) : 1 - 2